Comparisons of sequences and structures suggested several possible sites for zinc binding.
The magnitude of the apparent K I in relation to the blood and platelet concentrations of Zn 2+ supports a physiological role for this ion in the regulation of anticoagulant activity of APC.
These findings broaden the understanding of this versatile serine protease and enable the future development of potentially more efficient anticoagulant APC variants for treatments of thrombotic diseases. 70-80-loop is accompanied by a conformational change that leads to an 6% decrease in tryptophan fluorescence. This interaction is required for the activation of protein C by the thrombin-thrombomodulin complex, and it also somewhat stabilizes the amidolytic activity of APC (8, 10) . A similar enhancement on the amidolytic activity by Mn 2+ ions has been observed. This effect is believed to be mediated via the Ca 2+ binding site in the serine protease domain of APC (11) . The amidolytic activity of APC is also modulated by Na + and it has been suggested that the 221-225 loop in the serine protease domain forms a binding site for this ion (12) . A previous report showing that Gla domain-less APC requires Na + for its amidolytic activity in the absence but not in the presence of Ca 2+ , suggested that an allosteric link between the Na + -and Ca 2+ -binding loops modulates the structure and function of APC (13) .
No metal ions have previously been reported to down-regulate the activity of APC. In the present investigation we found that Zn 2+ efficiently inhibits the activity of APC, with both a synthetic peptide and factor Va as substrates. We have therefore characterized the interaction of Zn 2+ with the enzyme, and its influence on the kinetics of the amidolytic reaction. Zn 2+ binding was accompanied by a 40% decrease in tryptophan fluorescence, which was used to determine the affinity of APC for Zn 2+ . Structural comparisons and other data are used to propose reasonable models for how the inhibition might arise. 
Materials and methods

Proteins
Human full-length APC and APC lacking the Gla-domain (Des-Gla APC) were purchased from Enzyme Research Laboratories (South Bend, IN, USA). The preparations were >90 % homogenous in 10 % SDS-PAGE under reducing conditions with the Laemmli system. Both the major and minor bands were subjected to peptide mapping by Maldi-Tof MS as described before (14) , verifying that all bands were APC. The active concentrations of the APC preparations, determined by stoichiometric titrations against protein C inhibitor (PCI) with a known active concentration (14, 15) , were used throughout this study. Human protein S, human -thrombin, human factor Xa, human prothrombin and bovine factor V/Va were purchased from Enzyme Research Laboratories (South Bend, IN, USA). The active concentrations of factor Xa and -thrombin were determined as described previously (14, 16) .
Experimental conditions
Enzyme assays and fluorescence measurements were conducted at 250.2C and pH 7.4 in 20 mM Tris-HCl buffer containing 0.1 M NaCl, 0.1 % PEG 8000, except assays containing phospholipid vesicles, for which the PEG was excluded. If indicated, various concentrations of EDTA or a divalent cation as a chloride or sulfate salt were added. The salts used were PA grade from Merck. Unless noted otherwise, all Zn 2+ was added as ZnCl 2 . The water used in buffers had first been purified by the central water purification system at the Uppsala Biomedical Center, followed by purification in a Milli-Q instrument (Millipore), and had a resistance of 18.2 mega Ohm/cm. Mölndal, Sweden). The increase in absorbance due to product formation was monitored for 60 seconds at 405 nm. For APC activity, all preincubations were done with at least 100 nM APC, a concentration at which the enzyme was stable under the conditions used. The enzyme was then diluted to 1-2 nM in buffer containing S-2366 at the start of the measurement. The activities of thrombin and factor Xa were measured by similar assays but with the use of the chromogenic peptide substrates S-2238 and S-2222, respectively (Haemochrom Diagnostica, Mölndal, Sweden), as described before (14, 16) .
Kinetics of APC activity in the presence of Zn
2+
The effects of Zn 2+ on K M and k cat for the amidolytic activity of APC were determined by measuring APC activity by the chromogenic assay in the presence of either 10 M Zn 2+ , 100 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The effect of the interaction of Zn 2+ on the fluorescence of APC was analysed by measurements of fluorescence spectra for APC and des-Gla APC. The optimal  ex was first determined to be 282 nm by excitation spectra. Emission spectra were subsequently measured from  em 300 to 450 nm at the optimal  ex with 2 and 4 nm excitation and emission bandwidths, respectively. The spectra were measured at 100-200 nM protein concentrations. were determined by fitting the titration data to the equilibrium binding equation by nonlinear least-squares analysis, as described before, assuming a 1:1 binding stoichiometry (15) .
Modeling of Zn ion into the catalytic module
Sequences similar to that of APC were located among the protein entries of GenBank (19) and aligned using CLUSTAL W (20) . All similar catalytic domain structures were obtained from the Protein Data Bank (PDB) (21) , then superimposed and compared with the programs LSQMAN (22) and O (23) . O was used to model the zinc ions and the structural figures were prepared using O and Molray (24) . 
Results
Effects of divalent cations on APC amidolytic activity
The amidolytic activity of APC was measured spectrophotometrically with the use of the chromogenic peptide substrate S-2366 (0.5 mM) in the presence of either EDTA or one of the metal salts MnCl 2 , MgCl 2 , NiCl 2 , CuSO 4 , and ZnCl 2 ( Fig. 1) . The effects of all the salts were determined at two concentrations, one corresponding to the physiological concentration of each metal ion in blood (25-28) and one which was the same for all the salts, i.e. 2.5 mM. 
Effects of Zn 2+ on APC cleavage of S-2366
The amidolytic activity of APC was studied at different substrate concentrations in the presence of either 100 M EDTA, 10 M ZnCl 2 , 2. (Table 1 ). These results demonstrate that the Gla-domain is not of major importance for the inhibitory effect of Zn 2+ on APC activity. When the amidolytic activity was measured in the presence of 2.5 mM Ca 2+ , the K I value for zinc inhibition of APC was 564 M. At saturating concentration of Zn 2+ , the APC activity was completely abolished.
To compare the effect of Zn 2+ on APC activity with that on the activity of procoagulant proteases whose cofactors APC degrades, thrombin and factor Xa activities in the presence of Zn 2+ were also measured. Only a slight decrease in the activities of these proteases was observed in the presence of Zn 2+ . The decreases in thrombin and factor Xa activities were 40 % at 2.5 mM Zn 2+ , corresponding to K I values of over 5 mM. The concentrations of Zn 2+ required for the inhibition of thrombin and factor Xa are thus at least two orders of magnitude higher than those required for the inhibition of APC.
The reversibility of the inhibitory effect of Zn 2+ on APC activity was determined by adding 20 M EDTA to an APC solution containing 10 M Zn 2+ . After the addition of 10 M Zn 2+ , the activity was 59  1 % of the control value and after further addition of EDTA, Figure 3A . The activity decreased much more rapidly in the absence than in the presence of Zn 2+ , demonstrating that this ion significantly lowered the ability of APC to inactivate factor Va.
The influence of the Zn 2+ concentration on the inactivation of factor Va was studied by a similar two-stage assay as described above but with varying concentrations of Zn 2+ and a fixed incubation time of 2 min. This experiment was done in the absence or presence of equimolar concentration of the cofactor for APC, protein S. In the absence of factor S, the amount of thrombin generated, reflecting the inhibition of APC activity, increased dosedependently in a hyperbolic manner from 0-100 M Zn 2+ (Fig. 3B) 
Effects of Zn 2+ on tryptophan fluorescence spectra
The effect of the interaction with Zn 2+ on the fluorescence of APC and des-Gla APC was assessed by measurements of tryptophan fluorescence emission spectra for APC and des-Gla APC ( EDTA to this solution, the fluorescence was restored to that of APC containing EDTA but not Zn 2+ (Fig. 4C ). These findings show that the decrease in fluorescence caused by the interaction of Zn 2+ with APC is fully reversible. Similar results were obtained when the reversibility of the Zn 2+ -induced decrease in fluorescence of des-GLA APC was studied. The catalytic machinery was inhibited by zinc ions both using a chromogenic peptide 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   18 found two clusters that are also candidates for ion-binding sites. One of these includes His48, Ser50, His107 and Trp51, as modeled in Fig. 6C . It is not clear whether the interaction of Zn 2+ with these residues would affect the catalytic machinery. His91, His241 and Trp237 comprise another cluster, but since the latter residues are also present in other blood clotting proteases, they are not likely to give an effect specific for APC. These sites, however, include residues less commonly involved in Zn 2+ binding. A potential Zn 2+ site includes residues in the 144-153 loop, i.e. His144/Glu148/Glu149A, and possibly Asp18. The loop is an insertion in APC relative to other sequences, but the proposed Zn 2+ -binding residues are not as strongly conserved in mammalian APC sequences as one would expect if the function is widespread. In this model, an extensive conformational change would be required to convey the information to the active site. Clearly, a number of structural, mutational and other studies will be required to understand the basis of zinc binding and inhibition.
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What is known about this topic?
 It is known that activated protein C (APC) has several binding sites for Ca 2+ , one in the serine protease domain, one in the EGF-1 domain and nine in the GLA domain. Additionally, APC has one Na + -binding site in the serine protease domain.  It is known that binding of Ca 2+ to the serine protease domain is required for the activation of protein C by the thrombin-thrombomodulin complex.
 The binding of Ca 2+ and Na + to the serine protease domain allosterically regulate APC, resulting in enhanced enzymatic activity.
What does this paper add?
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